2018 Drug Discontinuations

Drug Name/Manufacturer	Dose/Package size	Press Release Date	Reason Discontinued
Estropipate Tablets	0.75MG TABLETS (NDC 00591-0414-01), 1.5MG TABLETS (NDC 00591-0415-01), 3MG TABLETS (NDC 00591-0416-01)	1/5/2018	Discontinuation of the manufacture of the drug
Midodrine HCl Tablets	Midodrine HCl Tablets, 10mg (bottle of 100), (NDC 0185-0149-01), Midodrine HCl Tablets, 2.5mg (bottle of 100), (NDC 0185-0040-01), Midodrine HCl Tablets, 5mg (bottle of 100), (NDC 0185-0043-01), Midodrine HCl Tablets, 5mg (bottle of 500), (NDC 0185-0043-05)	1/5/2018	Sandoz Inc. has made a business decision to permanently discontinue Midodrine HCl Tablets. This decision was not related to efficacy, safety, or quality. Generic equivalents are available.
Nabumetone Tablets	Nabumetone Tablets, 500mg, 100 count container, (NDC 0185-0145-01), Nabumetone Tablets, 500mg, 500 count container, (NDC 0185-0145-05), Nabumetone Tablets, 750mg, 100 count container, (NDC 0185-0146-01), Nabumetone Tablets, 750mg, 500 count container, (NDC 0185-0146-05)	1/5/2018	Sandoz Inc. has made a business decision to permanently discontinue Nabumetone Tablets. This decision was not related to efficacy, safety, or quality. Generic equivalents are available.
Twynsta	80mg/10mg tablets in 30-count blister packs.	3/7/2018	The Company stated the discontinuation was a business decision and that the other tablet strengths are still available: 40mg/5mg, 40mg/10mg, and 80mg/5mg.
Sumavel DosePro	6mg/0.5mL formulation	2/27/2018	Endo has made a business decision to discontinue Sumavel DosePro (sumatriptan injection) 6mg/0.5mL. The 4mg/0.5mL formulation was previously discontinued in 2016; today's decision affecting the 6mg/0.5mL formulation is also not related to the product's quality, safety or efficacy.
Zinbryta® (daclizumab)	All	3/2/2018	On March 2, 2018 Biogen and AbbVie announced that they are voluntarily taking Zinbryta® (daclizumab) for relapsing multiple sclerosis (MS) NDC # 00074-0033-01 off the market worldwide because of mounting concerns about adverse events. Given the nature and complexity of adverse events being reported, characterizing the evolving benefit/risk profile of Zinbryta will not be possible going forward given the limited number of patients being treated. Therefore, Biogen and AbbVie believe it is in the best interest of patients to voluntarily withdraw worldwide marketing authorizations for Zinbryta.

BYDUREON® (exenatide extended-release)	For injectable suspension, for subcutaneous use; Single Dose Tray presentation; (2 mg) (NDC 0310-6520-04)	4/3/2018	The planned permanent discontinuance of the Bydureon Single Dose Tray inventory from the U.S. market is September 30, 2018. There are currently 2 other delivery options for exenatide-extended-release: the Bydureon® Dual Chamber Pen presentation (NDC 0310-6530-04) and Bydureon® BCise™ (NDC 0310-6540-04).
Olysio	150 mg Capsules	4/19/2018	Janssen announced the discontinuation of Olysio (simeprevir) due to a significant decline in utilization and the availability of effective therapies, such as pangenotypic combination regimens, which address the current medical need in treating hepatitis C virus (HCV) infection.
Talwin (pentazocine)	30 mg/mL injection	4/16/2018	The product discontinuation is not due to product quality, safety or efficacy concerns.
Altretamine Capsules	50 mg, 100 count bottle	9/26/2018	Altretamine capsules, 50 mg, 100 count bottle (NDC 62856-001-10) 09/26/2018 Product discontinued as of 24 September 2018.
Guanfacine Hydrochloride Tablets	1mg bottles of 30, 1 mg bottles of 100, 2 mg bottles of 30, 2 mg bottles of 500	9/26/2018	Unavailable. Estimated recovery: Q1-2019